There are no RSV vaccines, but numerous drugmakers are working toward one, and some have reached promising results, including Pfizer and GSK.
A global study of 37,000 adults aged 60 and older found Moderna’s investigative vaccine was 83.7 effective against two or more symptoms of RSV-associated lower respiratory tract disease, and it was 82.4 percent effective against at least three symptoms. No safety concerns were noted, according to Moderna.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.